FTC files amicus brief on blocking generic drugs

Pharmaceutical companies that make slight modifications to their products to obstruct generic competitors engage in exclusionary conduct and should be banned, the Federal Trade Commission argued in a brief filed in the US Court of Appeals for the Third Circuit. The FTC said this practice, known as “product hopping,” can